Key Points
- Korro Bio SVP Oliver Dolan sold 7,347 shares at an average price of $13.51, generating approximately $99,258. After the sale, he retained 16,252 shares, a 31.13% reduction in his position.
- Korro Bio shares opened at $13.06, with a market capitalization of about $192.4 million. The company recently reported quarterly EPS of -$1.07, beating the consensus estimate of -$1.34, but continues to post significant losses.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $16.71, compared with the stock’s recent trading level near $13.
Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) SVP Oliver Dolan sold 7,347 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $13.51, for a total value of $99,257.97. Following the completion of the sale, the senior vice president owned 16,252 shares in the company, valued at approximately $219,564.52. This represents a 31.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Oliver Dolan also recently made the following trade(s):
- On Wednesday, September 9th, Oliver Dolan sold 6 shares of Korro Bio stock. The stock was sold at an average price of $13.60, for a total value of $81.60.
Korro Bio Stock Performance
KRRO opened at $13.06 on Friday. The company has a market cap of $192.37 million, a price-to-earnings ratio of -1.31 and a beta of 3.09. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89. The business's fifty day moving average is $12.62 and its two-hundred day moving average is $12.32.
Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.27. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 114.26%. On average, analysts predict that Korro Bio, Inc. will post -4.97 EPS for the current fiscal year.
Hedge Funds Weigh In On Korro Bio
Several large investors have recently bought and sold shares of KRRO. Russell Investments Group Ltd. bought a new position in shares of Korro Bio in the third quarter valued at approximately $39,000. Wells Fargo & Company MN boosted its stake in Korro Bio by 45.5% during the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company's stock valued at $60,000 after purchasing an additional 2,352 shares in the last quarter. Guggenheim Capital LLC acquired a new position in shares of Korro Bio during the 4th quarter valued at $84,000. Jain Global LLC bought a new stake in shares of Korro Bio in the 4th quarter worth $85,000. Finally, Deutsche Bank AG lifted its holdings in shares of Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company's stock valued at $102,000 after buying an additional 9,027 shares during the period. Institutional investors and hedge funds own 13.18% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Citigroup started coverage on shares of Korro Bio in a research report on Monday, May 18th. They set a "buy" rating and a $21.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Korro Bio in a research note on Thursday, August 20th. Wall Street Zen upgraded Korro Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Lifesci Capital raised Korro Bio to a "strong-buy" rating in a report on Friday, May 29th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Korro Bio in a research report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Korro Bio presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.
Check Out Our Latest Report on Korro Bio
Korro Bio Company Profile
(
Get Free Report)
Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.
The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
